Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CLLS
stocks logo

CLLS

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
11.90M
-64.15%
-0.246
+44.51%
13.15M
+9.58%
-0.258
+43.06%
14.67M
-19.35%
-0.275
+14.58%
Estimates Revision
The market is revising No Change the revenue expectations for Cellectis S.A. (CLLS) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 80.22%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Up
up Image
+80.22%
In Past 3 Month
Wall Street analysts forecast CLLS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLLS is 6.00 USD with a low forecast of 4.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast CLLS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLLS is 6.00 USD with a low forecast of 4.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
2 Hold
0 Sell
Moderate Buy
Current: 4.830
sliders
Low
4.00
Averages
6.00
High
8.00
Current: 4.830
sliders
Low
4.00
Averages
6.00
High
8.00
Wells Fargo
Nick Abbott
Equal Weight
maintain
$3 -> $4
2025-10-20
Reason
Wells Fargo
Nick Abbott
Price Target
$3 -> $4
2025-10-20
maintain
Equal Weight
Reason
Wells Fargo analyst Nick Abbott raised the firm's price target on Cellectis to $4 from $3 and keeps an Equal Weight rating on the shares. The firm says new data from DL3 of ALL study are promising, with high CR/CRi & MRD-ve rates in patients with few options. Clarity on regulatory path is also positive, Wells adds. Pivotal Phase 2 execution is now key, with first data Q4 2026 and BLA filing in the second half of 2028, along with clarity on market size/opportunity.
Barclays
Gena Wang
maintain
$4 -> $8
2025-10-17
Reason
Barclays
Gena Wang
Price Target
$4 -> $8
2025-10-17
maintain
Reason
Barclays analyst Gena Wang raised the firm's price target on Cellectis to $8 from $4 and keeps an Overweight rating on the shares. The company's research and development day provided updates on lasme-cel's "promising" efficacy data, the analyst tells investors in a research note.
Barclays
Overweight
downgrade
$5 -> $4
2025-05-13
Reason
Barclays
Price Target
$5 -> $4
2025-05-13
downgrade
Overweight
Reason
Barclays lowered the firm's price target on Cellectis to $4 from $5 and keeps an Overweight rating on the shares. The company's Q1 was largely incremental with key pipeline programs on track, the analyst tells investors in a research note. The firm says Cellectis has a cash runway into the second half of 2027.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Cellectis SA (CLLS.O) is -4.72, compared to its 5-year average forward P/E of -1.97. For a more detailed relative valuation and DCF analysis to assess Cellectis SA 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.97
Current PE
-4.72
Overvalued PE
0.30
Undervalued PE
-4.25

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-2.77
Current EV/EBITDA
-4.25
Overvalued EV/EBITDA
-0.71
Undervalued EV/EBITDA
-4.83

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
5.56
Current PS
4.59
Overvalued PS
9.18
Undervalued PS
1.94
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

CLLS News & Events

Events Timeline

(ET)
2025-11-07
16:32:54
Cellectis announces Q3 adjusted EPS of 2 cents compared to a loss of 22 cents in the previous year.
select
2025-11-03 (ET)
2025-11-03
09:24:50
Cellectis to share progress on eti-cel at ASH 2025
select
2025-03-13 (ET)
2025-03-13
18:11:13
Cellectis reports Q4 EPS (64c) vs (17c) last year
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
8.5
12-04Globenewswire
PinnedCellectis Reports Total Voting Rights of 105,406,812 as of November 30, 2025
  • Share Count Disclosure: As of November 30, 2025, Cellectis reported a total share count of 100,325,454, indicating stability in its capital structure, although specific market performance data was not provided.
  • Voting Rights Information: The total voting rights reached 105,406,812, reflecting shareholder engagement in corporate governance, which may influence future decisions at shareholder meetings.
  • Enhanced Market Transparency: This disclosure aligns with Euronext Growth market transparency requirements, bolstering investor confidence in Cellectis and potentially attracting new investors.
  • Clear Communication Channels: Cellectis has provided contact information for several executives, ensuring timely access to information for investors and media, thereby enhancing interaction with external stakeholders.
[object Object]
Preview
3.5
11-20Benzinga
Reasons Behind the Rise in Cellectis Stock Today

  • Cellectis' Research Breakthrough: Cellectis A/S published findings in Nature Communications demonstrating that circular single-stranded DNA (CssDNA) serves as an efficient non-viral DNA donor template for gene insertion in hematopoietic stem and progenitor cells (HSPCs), offering a promising alternative to traditional viral vectors.

  • Enhanced Gene Insertion Efficiency: The study revealed that CssDNA achieved 3-5 times higher knock-in efficiency compared to linear single-stranded DNA (LssDNA), with over 40% success, and can insert genes at multiple loci in HSPCs and other therapeutic cell types.

  • Comparative Advantages: CssDNA-edited HSPCs showed a greater ability to engraft and maintain gene edits in murine models compared to those edited with AAV6, highlighting its potential for long-term therapeutic benefits.

  • Financial Position: As of September 30, 2025, Cellectis reported $225 million in cash and equivalents, which is expected to fund operations into the second half of 2027, while its stock price increased by 8.27% to $4.45.

[object Object]
Preview
3.5
11-19Yahoo Finance
Cellectis Releases Article in Nature Communications on a Non-Viral Gene Editing Method for Effective Gene Insertion in Hematopoietic Stem Cells

  • Cellectis' New Gene Editing Technique: Cellectis has published research demonstrating that circular single-stranded DNA (CssDNA) serves as an efficient non-viral DNA donor template for gene insertion in hematopoietic stem and progenitor cells (HSPCs), achieving 3-5 times higher knock-in efficiency compared to linear single-stranded DNA.

  • Advantages Over Traditional Methods: The CssDNA method allows for the insertion of genes at multiple loci in HSPCs and shows improved engraftment and maintenance of gene edits in murine models compared to traditional viral vector methods like AAV6, marking a significant advancement in non-viral gene therapy.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Cellectis SA (CLLS) stock price today?

The current price of CLLS is 4.83 USD — it has increased 3.65 % in the last trading day.

arrow icon

What is Cellectis SA (CLLS)'s business?

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.

arrow icon

What is the price predicton of CLLS Stock?

Wall Street analysts forecast CLLS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLLS is 6.00 USD with a low forecast of 4.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Cellectis SA (CLLS)'s revenue for the last quarter?

Cellectis SA revenue for the last quarter amounts to NaN USD, decreased % YoY.

arrow icon

What is Cellectis SA (CLLS)'s earnings per share (EPS) for the last quarter?

Cellectis SA. EPS for the last quarter amounts to USD, decreased % YoY.

arrow icon

What changes have occurred in the market's expectations for Cellectis SA (CLLS)'s fundamentals?

The market is revising No Change the revenue expectations for Cellectis S.A. (CLLS) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 80.22%.
arrow icon

How many employees does Cellectis SA (CLLS). have?

Cellectis SA (CLLS) has 224 emplpoyees as of December 05 2025.

arrow icon

What is Cellectis SA (CLLS) market cap?

Today CLLS has the market capitalization of 483.60M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free